574 ONM-400, a novel approach for interleukin-2 therapy using a ph-activated nanoparticle targeting metabolic acidosis in solid cancers

• Jason Miller,
• Xinliang Ding,
• Ashley Campbell,
• Tian Zhao,
• Qingtai Su,
• Stephen Gutowski,
• Drew Robinson

Affiliations

Jason Miller

1OncoNano Medicine Inc., Dallas, TX, USA

Xinliang Ding

1OncoNano Medicine Inc., Dallas, TX, USA

Ashley Campbell

1OncoNano Medicine Inc., Dallas, TX, USA

Tian Zhao

1OncoNano Medicine Inc., Dallas, TX, USA

Qingtai Su

1OncoNano Medicine, Inc., Fort Worth, TX, USA

Stephen Gutowski

1OncoNano Medicine, Inc., Fort Worth, TX, USA

Drew Robinson

1OncoNano Medicine, Inc., Fort Worth, TX, USA